TARDBP and amyotrophic lateral sclerosis: The intricate molecular mechanisms underlying these conditions—including Aβ plaques in AD, α-synuclein Lewy bodies in PD, and TDP-43 proteinopathy in ALS—necessitate innovative approaches for early detection and targeted intervention.